FIELD: medicine, pharmacy. SUBSTANCE: invention proposes aqueous solution containing erythropoietin at concentration 500-4000 IU/1 ml, dextran of molecular mass 30000-60000 Da at concentration 6-10 wt.-%, sodium citrate and citric acid to obtain isotonicity and pH value of solution 6.5-7.5. Solution can contain additionally 5 wt.-% of mannitol or glucose. Invention provides to get useful life of solution up to 2 years under storage conditions at 2-8 C. Obtained stable erythropoietin solution can be used for treatment of patients with anemia. EFFECT: enhanced efficiency. 3 cl, 2 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEUROLOGIC DISEASES | 2007 |
|
RU2335296C1 |
IMMUNOMODELLING PREPARATION FOR INJECTION-FREE APPLICATION | 2001 |
|
RU2197986C2 |
METHOD FOR ERYTHROPOIETIN PREPARATION | 0 |
|
SU1651909A1 |
TABLET FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN | 2000 |
|
RU2182830C1 |
TEST SYSTEM FOR DIAGNOSTICS OF AGENTS OF ACUTE RESPIRATORY VIRAL INFECTIONS | 2019 |
|
RU2733379C1 |
STRAIN OF CULTIVABLE HYBRID MUS MUSCULUS CELLS FOR PRODUCING MONOCLONAL ANTIBODIES TO HUMAN INTERLEUKIN | 0 |
|
SU1472498A1 |
METHOD OF RECOMBINANT PROTEIN LIQUID MEDICINAL FORM PREPARING | 2001 |
|
RU2180233C1 |
SET FOR QUANTITATIVE DETERMINATION OF AVERMECTINS VIA SINGLE-STEP COMPETITIVE ENZYME-IMMUNOASSAY | 2009 |
|
RU2416094C1 |
METHOD FOR IMMUNOFLUORESCENT DETECTION OF PROTECTIVE ANTIGEN OF ANTHRAX AGENT | 2011 |
|
RU2478970C1 |
STRAIN OF CULTIVABLE HYBRID MUS MUSCULUS CELLS FOR PRODUCING MONOCLONAL ANTIBODIES TO HUMAN INTERLEUKIN | 0 |
|
SU1472499A1 |
Authors
Dates
1999-04-10—Published
1998-07-20—Filed